Weatherly Asset Management L. P. Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Weatherly Asset Management L. P. reduced its stake in Pfizer by 1.01% during the most recent quarter end. The investment management company now holds a total of 39,952 shares of Pfizer which is valued at $1,329,203 after selling 406 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Pfizer makes up approximately 0.45% of Weatherly Asset Management L. P.’s portfolio.

Pfizer closed down -0.05 points or -0.15% at $33 with 2,60,94,478 shares getting traded on Wednesday. Post opening the session at $32.98, the shares hit an intraday low of $32.9 and an intraday high of $33.21 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Cohen Klingenstein reduced its stake in PFE by selling 867 shares or 1.96% in the most recent quarter. The Hedge Fund company now holds 43,354 shares of PFE which is valued at $1,442,388. Pfizer makes up approx 0.27% of Cohen Klingenstein’s portfolio.Jacobs Coca reduced its stake in PFE by selling 6,548 shares or 3.1% in the most recent quarter. The Hedge Fund company now holds 204,532 shares of PFE which is valued at $6,647,290. Pfizer makes up approx 1.58% of Jacobs Coca’s portfolio.Vigilant Capital Management reduced its stake in PFE by selling 1,784 shares or 3.41% in the most recent quarter. The Hedge Fund company now holds 50,590 shares of PFE which is valued at $1,613,315. Pfizer makes up approx 0.33% of Vigilant Capital Management’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.